Upperton Pharma Solutions invests US$6.3 million (£5million) to expand its sterile drug manufacturing capacity.
The newly designed sterile facility will incorporate advanced VHP isolation technology to facilitate GMP fill-finish operations for sterile drug products, encompassing both biologics and small molecules. This expansion aligns with the existing comprehensive services, including full-service formulation development and quality control labs.
This expansion includes a new 7,000 sqft sterile manufacturing facility. The investment in sterile drug product manufacturing complements the current service portfolio, offering formulation development for various dosage forms, clinical trial supply, and niche-scale commercial manufacture for non-sterile products.
The facility is dedicated to producing aseptic and terminally sterilised small-volume liquids intended for parenteral, ocular, and pulmonary delivery.
This investment addresses a significant industry gap by providing small batches of sterile drug products crucial for early clinical trials.
Construction of the facility is set to commence in February 2024, and the commissioning and validation are targeted for early Q4/2024 completion.
Name Upperton Pharma Solutions
Budget US$6.3 million (£5million)